BioCentury | Feb 11, 2019
Distillery Therapeutics

Neurology

...Next steps by Bayer could include testing BAY 1316957 in other mouse models of pain. AskAt Inc....
...PTGER4 antagonist ARY-007 in Phase II testing for pain and Phase I testing for allergy. AskAt...
BioCentury | Dec 15, 2017
Finance

Kyndred spirits

...which have different needs and trajectories for funding,” he said. Arrys exclusively licensed ARY-007 from AsKat Inc....
BioCentury | Dec 15, 2017
Financial News

Kyn, Arrys raise series A rounds from Atlas, Orbimed

...holds an exclusive license to ARY-007 (AAT-007), a prostaglandin E2 (PGE2) receptor EP4 antagonist, from AsKat Inc....
BioCentury | Dec 14, 2017
Financial News

Kyn, Arrys raise series A rounds from Atlas, OrbiMed

...holds an exclusive license to ARY-007 (AAT-007), a prostaglandin E2 (PGE2) receptor EP4 antagonist, from AsKat Inc....
BioCentury | Dec 10, 2012
Company News

RaQualia gastrointestinal news

...RaQualia will transfer its science innovation division to a newly created and wholly owned subsidiary, AskAt Inc....
Items per page:
1 - 5 of 5
BioCentury | Feb 11, 2019
Distillery Therapeutics

Neurology

...Next steps by Bayer could include testing BAY 1316957 in other mouse models of pain. AskAt Inc....
...PTGER4 antagonist ARY-007 in Phase II testing for pain and Phase I testing for allergy. AskAt...
BioCentury | Dec 15, 2017
Finance

Kyndred spirits

...which have different needs and trajectories for funding,” he said. Arrys exclusively licensed ARY-007 from AsKat Inc....
BioCentury | Dec 15, 2017
Financial News

Kyn, Arrys raise series A rounds from Atlas, Orbimed

...holds an exclusive license to ARY-007 (AAT-007), a prostaglandin E2 (PGE2) receptor EP4 antagonist, from AsKat Inc....
BioCentury | Dec 14, 2017
Financial News

Kyn, Arrys raise series A rounds from Atlas, OrbiMed

...holds an exclusive license to ARY-007 (AAT-007), a prostaglandin E2 (PGE2) receptor EP4 antagonist, from AsKat Inc....
BioCentury | Dec 10, 2012
Company News

RaQualia gastrointestinal news

...RaQualia will transfer its science innovation division to a newly created and wholly owned subsidiary, AskAt Inc....
Items per page:
1 - 5 of 5